Common Contracts

Second amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain

Co-Development and Licensing Agreement • March 12th, 2021

• Contract Type
  Co-Development and Licensing Agreement
• Filed
  March 12th, 2021

This Amendment No. 2 to the Collaboration and License Agreement (this “Amendment No. 2”) is made effective as of October 1, 2008 (the “Amendment No. 2 Effective Date”) by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“AstraZeneca”). POZEN and AstraZeneca may be referred to herein individually as a “Party,” or collectively as the “Parties.”